



20 April 2021



Dear [REDACTED]

### Official Information Act Request

You have asked for information about Prostate Specific Membrane Antigen (PSMA) PET-CT.

*Please can you advise whether PSMA (Prostate Specific Membrane Antigen) PET-CT is funded by the DHB or only available privately?*

*If publicly funded, please can you advise whether there are criteria that must be met. For example:*

- *For staging of high risk and unfavourable intermediate risk prostate cancer before definitive local therapy.*
- *For restaging of PSA recurrence ( $\geq 0.2$ ng/ml).*

Northland DHB funds PSMA PET-CT. Access criteria are Northern region variants from the National PET guidelines.

- PSMA PET in High Risk prostate Cancer (PSA>20, Gleason>7, T3c) to determine if the patient is a candidate for radical prostatectomy
- PSMA PET Biochemical recurrence (PSA>0.5) after definitive treatment, Conventional imaging indeterminate.

Northland DHB supports the open disclosure of information to assist public understanding of how we deliver our services. This includes proactive publication of anonymised Official Information Act responses on our website from 10 working days after they have been provided to you. Personal or identifying information will be redacted from any response published online. If you consider there are good reasons why this response should not be publicly available we will consider your views.

If you have any queries about Northland DHB's response to your information request please contact me.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Nick Chamberlain', written over a light green circular watermark.

**Dr Nick Chamberlain**  
Chief Executive